Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab with Radiotherapy in Head and Neck Cancer
NCT03162731Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03 up to 6 months. Started May 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03162731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162731.